Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial-Reference-Cited by-同舟云学术

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Published:2022-05 Issue:5 Volume:10 Page:330-340
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Ostadal Petr,Steg Philippe Gabriel,Poulouin Yann,Bhatt Deepak L,Bittner Vera A,Chua Terrence,Diaz Rafael,Goodman Shaun G,Huo Yong,Jukema Johan Wouter,Karpov Yuri,Pordy Robert,Scemama Michel,Szarek Michael,White Harvey D,Schwartz Gregory G

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference31 articles.

1. Harmonizing the Metabolic Syndrome

2. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence;Ford;Diabetes Care,2005

3. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis;Galassi;Am J Med,2006

4. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies;Gami;J Am Coll Cardiol,2007

5. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;Circulation,2019

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes;Cardiovascular Drugs and Therapy;2024-06-22

2. Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis;Frontiers in Pharmacology;2024-05-17

3. How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?;Current Opinion in Lipidology;2024-03-20

4. Association of systemic immunity-inflammation index with metabolic syndrome in U.S. adult: a cross-sectional study;BMC Geriatrics;2024-01-15

5. Progress of Clinical Research on Lipoprotein a and Cardiovascular Diseases;Advances in Clinical Medicine;2024